Mitochondrial potassium channels as pharmacological target for cardioprotective drugs

Medicinal Research Reviews

Volumn 35, Issue 3, 2015, Pages 520-553

  Testai, L ^a   Rapposelli, S ^a   Martelli, A ^a   Breschi, M C ^a   Calderone, V ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cardioprotective drugs; Ischemia reperfusion; Mitochondrial potassium channels; Myocardial injury; Potassium channel activators

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CARDIOVASCULAR AGENT; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MITOCHONDRIAL POTASSIUM CHANNEL; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; CALCIUM; CARDIOTONIC AGENT; MITOCHONDRIAL K(ATP) CHANNEL;

ACTION POTENTIAL DURATION; AGING; ARTICLE; CELL DEATH; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SELECTIVITY; ELECTRON TRANSPORT; HEART MITOCHONDRION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; INNER MEMBRANE; ISCHEMIA INDUCED CELL DEATH; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REPERFUSION INDUCED CELL DEATH; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; HEART MUSCLE; METABOLISM; MITOCHONDRION; MOUSE; PATHOLOGY;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CELL DEATH; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MICE; MITOCHONDRIA; MITOCHONDRIA, HEART; MYOCARDIUM; POTASSIUM CHANNELS; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84926472240     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21332     Document Type: Article

References (238)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Vanlangenkker N, Vanden BT, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008;8:207-220.
3. Vanlangenakker N, Vanden BT, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012;19:75-86.
4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-1135.
5. Halestrap AP, Kerr PM, Javadov S, Woodfield KY. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1998;1366:79-94.
6. Halestrap AP, Clarke SJ, Javadov S. Mitochondrial permeability transition pore opening during myocardial reperfusion-A target for cardioprotection. Cardiovasc Res 2004;61:372-385.
7. Solaini G, Harris DA. Biochemical dysfunction in heart mitochondria exposed to ischemia and reperfusion. Biochem J 2005;390:377-394.
8. Kevin LG, Camara AKS, Riess ML, Novalija E, Stowe DF. Ischemic preconditioning alters real-time measure of O2-radicals in intact hearts with ischemia and reperfusion. Am J Physiol 2003;284:H566-H574.
9. Kalogeris T, Baines CP, Krenz, Korthius RJ. Cell biology of ischemia/reperfusion injury. Intl Rev Cell Mol Biol 2012;298:229-317.
10. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res 2014;114:524-537.
11. Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: Fixing a hole. Cardiovasc Res 2006;70:191-199.
12. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
13. Hunter DR, Haworth RA, Southard JH. Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem 1976;251:5069-5077.
14. Crompton M, Andreeva L. On the involvement of a mitochondrial pore in reperfusion injury. Basic Res Cardiol 1993;88:513-523.
15. Griffithsn EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. Cardiovasc Res 1993;25:1461-1469.
16. Heusch G, Boegler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: The holy grail of cardioprotection. Basic Res Cardiol 2010;105:151-154.
17. Halestrap AP. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7-Implications for the protective effect of low pH against chemical and hypoxic cell damage. Biochem J 1991;278:715-719.
18. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction. Herz 2008;33:88-100.
19. ++ overloading trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol 2006;290:H2024-H2034.
20. Kimura Y, Iyengar R, Subramanian R, Cordis GA, Das DK. Preconditioning of the heart by repeated stunning: Attenuation of post-ischemic dysfunction. Basic Res Cardiol 1992;87:128-138.
21. Scorrano L, Petronilli V, Bernardi P. On the voltage dependence of the mitochondrial permeability transition pore. A critical appraisal. J Biol Chem 1997;272:12295-12299.
22. Ryu SY, Peixoto PM, Teijido O, Dejean LM, Kinnally KW. Role of mitochondrial ion channels in cell death. Biofactors 2010;36:255-263.
23. Zoratti M, Szabò I, De Marchi U. Mitochondrial permeability transitions: How many doors to the house? Biochim Biophys Acta 2005;1706:40-52.
24. Bernardi P. Mitochondrial transport of cations: Channels, exchangers and permeability transition. Physiol Rev 1999;79:1127-1155.
25. Doran E, Halestrap AP. Cytochrome c release from isolated rat liver mitochondria can occur independently of outer-membrane rupture: Possible role of contact sites. Biochem J 2000;348:343-350.
26. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001;2:63-67.
27. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KHH, Halestrap AP. Ischemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-524.
28. Griffiths EJ, Halestrap AP. Protection by cyclosporine A of ischemia-reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25:1461-1469.
29. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010;24:85-87.
30. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mawton N, Elbelghiti R, Cung T, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
31. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
32. Edwards RJ, Saurin AT, Rakhit RD, Marber MS. Therapeutic potential of ischemic preconditioning. Br J Clin Pharmacol 2000;50:87-97.
33. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-1151.
34. Kloner RA, Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res 2006;70:297-307.
35. Heusch G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet 2013;381:166-175.
36. Millar CG, Baxter GF, Thiemermann C. Protection of the myocardium by ischemic preconditioning: Mechanisms and therapeutic implications. Pharmacol Ther 1996;69:143-151.
37. Schwartz LM, Jennings RB, Reimer KA. Premedication with the opioid analgesic butorphanol raises the threshold for ischemic preconditioning in dogs. Basic Res Cardiol 1997;92:106-114.
38. Bianes CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping P. Protein kinase C epsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 2003;92:873-880.
39. Minamino T. Cardioprotection from ischemia-reperfusion injury. Basic Transl Res Circ J 2012;76:1074-1082.
40. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
41. Skyschally A, van Caster P, Iliodromtis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning: Experimental models and protocol algorithms. Basic Res Cardiol 2009;104:469-483.
42. Staat P, Rioufol G, Piot C Cottin Y, Cung TT, L'huillir I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation 2005;112:2143-2148.
43. ++ overload. Am J Physiol Heart Circ Physiol 2005;288:H1900-H1908.
44. ATP-dependent mechanism: First demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007;292:H1883-H1890.
45. Li CM, Zhang XH, Ma XJ, Luo M. Limb ischemic postconditioning protects myocardium from ischemia-reperfusion injury. Scand Cardiovasc J 2006;40:312-317.
46. Kerendi F, Kin H, Halkos ME, Jiang R, Zattas AJ, Zhao ZQ, Guyton RA, Vinten-Johansen J. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100:404-412.
47. Zhao ZQ. Postconditioning in reperfusion injury: A status report. Cardiovasc Drugs Ther 2010;24:265-279.
48. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhaused M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: A single randomized, double-blind, controlled trial. Lancet 2013;382:597-604.
49. Vinten-Johansen, Shi W. The science and clinical translation of remote postconditioning. J Cardiovasc Med 2013;14:206-213.
50. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, Wang HS, Li WM, Xu L, Ni ZH, Liu SH, Zhang L, Jia HM, Vinten-Johansen J, Zhao ZQ. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007;19:424-430.
51. Liu G, Thornton J, Van Winkle D, Stanley A, Olsson R, Downey J. Protection again infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
52. Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glybenclamide-sensitive mechanism in dogs. Am J Physiol Heart Circ Physiol 1993;264:H2221-H2225.
53. Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: A graded phenomenon: Its relation to adenosine and bradykinin. Circulation 1998;98:1022-1029.
54. Zhang WM, Jin WQ, Wong TM. Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma. J Mol Cell Cardiol 1996;28:1547-1554.
55. Weil J, Eschenhagen T, Fleige G, Mittmann C, Orthey E, Scholz H. Localization of preproenkephalin mRNA in rat heart: Selective gene expression in left ventricular myocardium. Am J Physiol 1998;275:H378-H384.
56. ATP channels. Am J Physiol 1995;268:H2294-H2301.
57. Schwarz ER, Whyte WS, Kloner RA. Ischemic preconditioning. Curr Opin Cardiol 1997;12:475-481.
58. Fryer RM, Schultz JE, Hsu AK, Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. Am J Physiol 1999;276:H1229-H1235.
59. Wang GY, Wu S, Pei JM, Yu XC, Wong TM. Kappa- but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 2001;280:H384-H391.
60. Lochner A, Marais E, Genade S, Moolman JA. Nitric oxide: A trigger for classic preconditioning? Am J Physiol Heart Circ Physiol 2000;279:H2752-H2765.
61. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23.
62. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-1918.
63. Heusch G, Boegler K, Schulz R. Cardioprotection, nitric oxide, protein kinases, and mitochondria. Circulation 2008;118:1915-1919.
64. ATP channels. Can J Physiol Pharmacol 2007;85:1248-1253.
65. Murriel CL, Mochly-Rosen D. Opposing roles of delta and epsilon PKC in cardiac ischemia and reperfusion: Targeting the apoptotic machinery. Arch Biochem Biophys 2003;420:246-254.
66. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 2001;98:11114-11119.
67. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008;321:1493-1495.
68. Ping P, Zhang J, Qui Y, Tang XL, Manchikalapuldi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms and in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 1997;81:404-414.
69. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P. Mitochondrial PKC epsilon and MAPK form signaling modules in the murine heart. Enhanced mitochondrial PKC-epsilon MAPK interactions and differential MAPK activation in PKC epsilon-induced cardioprotection. Circ Res 2002;90:390-397.
70. Churchill EN, Murriel CL, Chen CH, Mochly-Rosen D, Szweda LI. Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ Res 2005;97:78-85.
71. Ikeno F, Inagaki K, Rezaee M, Mochly-Rosen D. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res 2007;73:699-709.
72. Vahlhaus C, Schulz R, Post H, Onallah R, Heusch G. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res 1996;79:407-414.
73. Mochly-Rosen D, Grimes K. Myocardial salvage in acute myocardial infarction: Challenges in clinical translation. J Mol Cell Cardiol 2011;51:451-453.
74. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010;105:771-785.
75. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic preconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011;109:1302-1308.
76. + channel in the mitochondrial inner membrane. Nature 1991;352:244-247.
77. Ca-type in the inner mitochondrial membrane of a human glioma cell line. Biochem Biophys Res Commun 1999;257:549-554.
78. 2+-activated potassium channel (KCa3.1) in the inner mitochondrial membrane of human colon cancer cells. Cell Calcium 2009;45:509-516.
79. + channels in cardiac inner mitochondrial membrane. Science 2002;298:1029-1033.
80. + channels identified in guinea-pig cardiac inner mitochondrial membrane. Biochim Biophys Acta 2013;828:427-442.
81. Boengler K, Dodoni G, Rodriguez-Sinovas A, Cabestrero A, Ruiz-Meana M, Gres P, Konietzka I, Lopez-Iglesias C, Garcia-Dorado D, Di Lisa F, Heusch G, Schulz R. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 2005;67:234-244.
82. Miro-Casas E, Ruiz-Meana M, Agullo E, Stahlofen S, Rodriguez-Sinovas A, Cabestrero A, Jorge I, Torre I, Vazquez J, Boenlger K, Schulz R, Heusch G, Garcia-Dorado D. Connexin 43 in cardiomyocyte mitochondria contributes to mitochondrial potassium uptake. Cardiovasc Res 2009;83:747-756.
83. Boengler K, Ungefug E, Heusch G, Leybaert L, Schulz R. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol 2013;73:1-5.
84. Heinzel F, Luo Y, Li X, Boengler K, Buechert A, Garcia-Dorado D, Di Lisa F, Schulz R, Heusch G. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. Circ Res 2005;97:583-586.
85. Garlid KD. Opening mitochondrial K(ATP) in the heart-what happens, and what does not happen. Basic Res Cardiol 2000;95:275-279.
86. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288:H971-H976.
87. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 1998;273:18092-18098.
88. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-1775.
89. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 1995;26:145-152.
90. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995;25:40-50.
91. + blocker dofetilide. Am J Physiol 1996;271:H1207-H1214.
92. + channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
93. ATP channel. Fact or function? J Mol Cell Cardiol 2012;52:578-583.
94. + channels are involved in ischemic postconditioning in rat hearts. J Physiol Sci 2012;62:325-332.
95. ATP channel. Biochem Pharmacol 2010;79:39-47.
96. ATP channel during ischemia-reperfusion acidosis. Shock 2012;37:653-658.
97. ATP channels participate in the limitation of infarct size by cariporide. Naunyn Schmiedebergs Arch Pharmacol 2011;383:563-571.
98. ATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 2008;154:41-50.
99. Szabo I, Zoratti M. Mitochondrial channels: Ion fluxes and more. Physiol Rev 2014;94:519-608.
100. + channels. J Mol Cell Cardiol 2003;35:1339-1347.
101. Mitchell MB, Meng X, Ao L, Brown JM, Harken AH, Banerjee A. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res 1995;76:73-81.
102. Szewezyk A, Skaòska M, Glab B, Kulawiak B, Malinska D, Koskela-Piotrowska I, Kunz WS. Mitochondrial potassium channels: From pharmacology to function. Biochim Biophys Acta 2006;1757:715-720.
103. Ye B, Kroboth SL, Pu JL, Sims JJ, Aggarwal NT, McNally EM, Makielski JC, Shi NQ. Molecular identification and functional characterization of a mitochondrial sulfonylurea receptor 2 splice variant generated by intraexonic splicing. Circ Res 2009;105:1083-1093.
104. ATP channels in cell survival and death. J Mol Cell Cardiol 2005;39:7-16.
105. Foster DB, Ho AS, Rucker J, Garlid AO, Chen L, Sidor A, Garlid KD, O'Rourke B. Mitochondrial ROMK channel is a molecular component of mitoK(ATP). Circ Res 2012;111:446-454.
106. ATP channel openers: Structure-activity relationships and therapeutic potential. Med Res Rev 2004;24:213-266.
107. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-8799.
108. D'hahan N, Moreau C, Prost AL, Jacquet H, Alekseev AE, Terzic A, Vivaudou M. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP. Proc Natl Acad Sci USA 1999;96:12162-12167.
109. Pain T, Yang X, Critz S, Yue Y, Nakano A, Liu GS, Heusch G, Cohen MV, Downey JM. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ Res 2000;87:460-466.
110. ATP channels during metabolic inhibition by an indirect mechanism. Cardiovasc Res 2004;61:570-579.
111. Holmuhamedov EL, Jahangir A, Oberlin A, Komarov A, Colombini M, Terzic A. Potassium channel openers are uncoupling protonophores: Implication in cardioprotection. FEBS Lett 2004;568:167-170.
112. Lim KH, Javadov SA, Das M, Clarke SJ, Suleiman MS, Halestrap AP. The effects of ischaemic preconditioning, diazoxide and 5-hydroxydecanoate on rat heart mitochondrial volume and respiration. J Physiol 2002;545:961-974.
113. Wojtovich AP, Nehrke KW, Brookes PS. The mitochondrial complex II and ATP-sensitive potassium channel interaction: Quantitation of the channel in heart mitochondria. Acta Biochim Pol 2010;57:431-434.
114. ATP channels. Basic Res Cardiol 2009;104:121-129.
115. Antoine MH, Berkenboom G, Fang ZY, Fontaine J, Herchuelz A, Lebrun P. Mechanical and ionic response of rat aorta to diazoxide. Eur J Pharmacol 1992;216:299-306.
116. Pirotte B, de Tullio P, Lebrun P, Antoine MH, Fontaine J, Masereel B, Schynts M, Dupont L, Herchuelz A, Delarge J. 3-(Alkylamino)-4H-pyrido4, 3-e.-1, 2, 4-thiadiazine 1, 1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: A new class of potassium channel openers? J Med Chem 1993;36:3211-3213.
117. Atwal KS, Grover GJ, Ahmed SZ, Ferrara FN, Harper TW, Kim KS, Sleph PG, Dzwonczyk S, Russell AD, Moreland S, McCullough JR, Russell AD, Normandin DE. Cardioselective anti-ischemic ATP-sensitive potassium channel openers. J Med Chem 1993;36:3971-3974.
118. Grover GJ, Atwal KS. Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia. Cardiovasc Drug Rev 2002;20:121-136.
119. ATP) openers: Benzopyranyl indoline and indole analogues. Eur J Med Chem 2003;38:459-471.
120. Jung YS, Jung YS, Kim MY, Kim MH, Lee S, Yi KY, Yoo SE, Lee SH, Baik EJ, Moon CH, Cho JP. KR-31466, a benzopyranylindol analog, attenuates hypoxic injury through mitochondrial K(ATP) channel and protein kinase C activation in heart-derived H9c2 cells. J Pharmacol Sci 2003;92:13-18.
121. Breschi MC, Calderone V, Digiacomo M, Manganaro M, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A. Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel. J Med Chem 2008;51:6945-6954.
122. Breschi MC, Calderone V, Martelli A, Minutolo F, Rapposelli S, Testai L, Tonelli F, Balsamo A. New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties. J Med Chem 2006;49:7600-7602.
123. Rapposelli S, Breschi MC, Calderone V, Digiacomo M, Martelli A, Testai L, Vanni M, Balsamo A. Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia. Eur J Med Chem 2011;46:966-973.
124. Rapposelli S, Calderone V, Cirilli R, Digiacomo M, Faggi C, La Torre F, Manganaro M, Martelli A, Testai L. Enantioselectivity in cardioprotection induced by (S)- (-)-2, 2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane. J Med Chem 2009;52:1477-1480.
125. + channel opening requires superoxide radical generation. Am J Physiol Heart Circ Physiol 2006;290:H434-H40.
126. + channels triggers early and delayed preconditioning against I/R injury independent of NOS in mice. Am J Physiol Heart Circ Physiol 2004;287:H2070-H2077.
127. Cao CM, Xia Q, Gao Q, Chen M, Wong TM. Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning. J Pharmacol Exp Ther 2005;312:644-650.
128. Liu Y, Kalogeris T, Wang M, Zuidema MY, Wang Q, Dai H, Davis MJ, Hill MA, Korthius RJ. Hydrogen sulfide preconditioning or neutrophil depletion attenuates ischemia-reperfusion-induced mitochondrial dysfunction in rat small intestine. Am J Physiol Gastrointest Liver Physiol 2012;302:G44-G54.
129. Zuidema MY, Yang Y, Wang M, Kalogeris T, Liu Y, Meininger CJ, Hill MA, Davis MJ, Korthius RJ. Antecedent hydrogen sulfide elicits an anti-inflammatory phenotype in postischemic murine small intestine: Role of BK channels. Am J Physiol Heart Circ Physiol 2010;299:H1554-H1567.
130. + channels. Microcirulation 2010;17:427-438.
131. Bednarczyk P, Barker GD, Halestrap AP. Determination of the rate of K(+) movement through potassium channels in isolated rat heart and liver mitochondria. Biochim Biophys Acta 2008;1777:540-548.
132. Bentzen BH, Osadchii O, Jespersen T, Hansen RS, Olesen SP, Grunnet M. Activation of big conductance Ca(2+)-activated K (+) channels (BK) protects the heart against ischemia-reperfusion injury. Pflugers Arch 2009;457:979-988.
133. + channel opening. Am J Physiol Cell Physiol 2010;298:C530-C541.
134. ++ channels in rat ventricular myocytes. Biochem Biophys Res Commun 2007;326:31-36.
135. + channel modulators NS 1619 1, 3-dihydro-1-2-hydroxy-5-(trifluoromethyl)phenyl-5-(trifluoromethyl)-2H-benzimidazol-2-one and isopimaric acid. J Pharmacol Exp Ther 2007;321:1075-1084.
136. Edwards G, Niederste-Hollenberg A, Schneider J, Noack T, Weston AH. Ion channel modulation by NS1619, the putative BKCa channel opener, in vascular smooth muscle. Br J Pharmacol 1994;113:1538-1547.
137. + channels by novel benzimidazolone. Eur J Pharmacol 1994;251:53-59.
138. + channels. Mol Pharmacol 2007;72:1033-1044.
139. Debska G, Kicinska A, Skalska J, Szewczyk A, May R, Elger CE, Kunz WS. Opening of potassium channels modulates mitochondrial function in rat skeletal muscle. Biochim Biophys Acta 2002;1556:97-105.
140. + fluxes through K(Ca) channels in heart mitochondria. Biochim Biophys Acta 2010;1797:71-80.
141. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V, Parker DT. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40:2525-2532.
142. Kulawiak B, Kudin AP, Szewczyk A, Kunz WS. BK channel openers inhibit ROS production of isolated rat brain mitochondria. Exp Neurol 2008;212:543-547.
143. + channel opener CGS7184 as a regulator of endothelial cell function. Eur J Pharmacol 2009;602:105-111.
144. 2+ release from the endoplasmic reticulum. Eur J Pharmacol 2012;690:60-67.
145. + channels in cardiac mitochondria. Am J Physiol Heart Circ Physiol 2005;289:H1635-H1642.
146. + channels in sildenafil-induced late cardioprotection. J Mol Cell Cardiol 2008;44:105-113.
147. Meera P, Wallner M, Jiang Z, Toro L. A calcium switch for the functional coupling between alpha (hslo) and beta subunits (K, V, Ca beta) of maxi K channels. FEBS Lett 1996;382:84-88.
148. Singh H, Lu R, Bopassa JC, Meredith AL, Stefani E, Toro L. MitoBK(Ca) is encoded by the Kcnma1 gene, and a splicing sequence defines its mitochondrial location. Proc Natl Acad Sci USA 2013;110:10836-10841.
149. + channels in cardiac myocytes: A mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 2005;111:198-203.
150. 2+-activated potassium channel (KCa3.1) in the innermitochondrial membrane of human colon cancer cells. Cell Calcium 2009;45:509-516.
151. + channel mtKCa3.1. Biochim Biophys Acta 2010;1797:260-1267.
152. Dolga AM, Netter MF, Perocchi F, Doti N, Meissner L, Tobaben S, Grohm J, Zischka H, Plesnila N, Decher N, Culmsee C. Mitochondrial small conductance SK2 channels prevent glutamate-induced oxytosis and mitochondrial dysfunction. J Biol Chem 2013;288:10792-10804.
153. + channels. J Med Chem 2008;51:7625-7634.
154. Szabò I, Bock J, Jekle A, Soddemann M, Adams C, Lang F, Zoratti M, Gulbins E. A novel potassium channel in lymphocyte mitochondria. J Biol Chem 2005;280:12790-12798.
155. + channel in macrophages. J Biol Chem 2006;281:37675-37685.
156. Bednarczyk P, Kowalczyk JE, Beresewicz M, Dołowy K, Szewczyk A, Zabłocka B. Identification of a voltage gated potassium channel in gerbil hippocampal mitochondria. Biochem Biophys Res Commun 2010;397:614-620.
157. Gulbins E, Szabo I, Baltzer K, Lang F. Ceramide-induced inhibition of T lymphocyte voltage-gated potassium channel is mediated by tyrosine kinases. Proc Natl Acad Sci USA 1997;94:7661-7666.
158. Leanza L, Zoratti M, Gulbins E, Szabò I. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr Med Chem 2012;19:5394-5404.
159. Szabò I, Zoratti M, Gulbins E. Contribution of voltage-gated potassium channels to the regulation of apoptosis. FEBS Lett 2010;584:2049-2056.
160. Leanza L, Henry B, Sassi N, Zoratti M, Chandy G, Gulbins E, Szabo I. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol Med 2012;4:1-17.
161. Leanza L, Trentin L, Becker KA, Frezzato F, Zoratti M, Semenzato G, Gulbins E, Szabo I. Clofazimine, Psora-4 andPAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocyteic leukemia. Leukemia 2013;27:1782-1785.
162. Szewczyk A, Jarmuszkiewicz W, Kunz WS. Mitochondrial potassium channels. IUBMB Life 2009;61:134-143.
163. Kajma A, Szewczyk A. A new pH-sensitive rectifying potassium channel in mitochondria from the embryonic rat hippocampus. Biochim Biophys Acta 2012;1817:1867-1878.
164. Rusznák Z, Bakondi G, Kosztka L, Pocsai K, Dienes B, Fodor J, Telek A, Gönczi M, Szucs G, Csernoch L. Mitochondrial expression of the two-pore domain TASK-3 channels in malignantly transformed and non-malignant human cells. Virchows Arch 2008;452:415-426.
165. Toczylowska-Maminska r, Olszewska A, Laskowski M, Bednarczyk P, Skowronek K, Szewczyk A. Potassium channel in the mitochondria of human keratinocytes. J Invest Dermatol 2014;134:764-772.
166. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
167. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23-29.
168. ATP channel opener. Eur J Pharmacol 2001;428:311-314.
169. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004;68:807-812.
170. ATP channels: Probing molecular identity and pharmacology. J Mol Cell Cardiol 2000;32:1911-1915.
171. Ma H, Huang X, Li Q, Guan Y, Yuan F, Zhang Y. ATP-dependent potassium channels and mitochondrial permeability transition pores play roles in the cardioprotection of theaflavin in young rat. J Physiol Sci 2011;61:337-342.
172. Zaugg M, Lucchinetti E, Spahn DR, Pasch T, Schaub MC. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 2002;97:4-14.
173. Van Allen NR, Krafft PR, Leitzke AS, Applegate RL, Tang J, Zhang JH. The role of volatile anesthetics in cardioprotection: A systematic review. Med Gas Res 2012;2:22. doi: 10.1186/2045-9912-2-22
174. 2+ overload during ischemia in guinea pig intact hearts: Reversal by 5-hydroxydecanoic acid. Anesth Analg 2002;95:1540-1546.
175. Riess ML, Novalija E, Camara AK, Eells JT, Chen Q, Stowe DF. Preconditioning with sevoflurane reduces changes in nicotinamide adenine dinucleotide during ischemia-reperfusion in isolated hearts: Reversal by 5-hydroxydecanoic acid. Anesthesiology 2003;98:387-395.
176. Stumpner J, Lange M, Beck A, Smul TM, Lotz CA, Kehl F, Roewer N, Redel A. Desflurane-induced post-conditioning against myocardial infarction is mediated by calcium-activated potassium channels: Role of the mitochondrial permeability transition pore. Br J Anaesth 2012;108:594-601.
177. + channels in rabbit hearts. J Pharmacol Exp Ther 2008;326:100-104.
178. Testai L, Martelli A, Marino A, D'Antongiovanni V, Ciregia F, Giusti L, Lucacchini A, Chericoni S, Breschi MC, Calderone V. The activation of mitochondrial BK potassium channels contributes to the protective effects of naringenin against myocardial ischemia/reperfusion injury. Biochem Pharmacol 2013;85:1634-1643.
179. Gao Q, Yang B, Ye ZG, Wang J, Bruce IC, Xia Q. Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin. Eur J Pharmacol 2007;574:179-184.
180. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 2001;276:4588-4596.
181. Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999;263:709-716.
182. Porteous CM, Logan A, Evans C, Ledgerwood EC, Menon DK, Aigbirhio F, Smith RA, Murphy MP. Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: Implications for mitochondria-specific therapies and probes. Biochim Biophys Acta 2010;1800:1009-1017.
183. Rodriguez-Cuenca S, Cochemé HM, Logan A, Abakumova I, Prime TA, Rose C, Vidal-Puig A, Smith AC, Rubinsztein DC, Fearnley IM, Jones BA, Pope S, Heales SJ, Lam BY, Neogi SG, McFarlane I, James AM, Smith RA, Murphy MP. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 2010;48:161-172.
184. Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S, Zoratti M, Paradisi C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett 2008;18:5594-5597.
185. Vyssokikh MY, Chernyak BV, Domnina LV, Esipov DS, Ivanova OY, Korshunova GA, Symonyan RA, Skulachev MV, Zinevich TV, Skulachev VP. SkBQ-Prooxidant addressed to mitochondria. Biochemistry (Mosc) 2013;78:1366-1370.
186. Adlam, VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005;19:1088-1095.
187. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal 2011;15:3021-3038.
188. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010;1201:96-103.
189. Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One 2013;8:e70575.
190. Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane-From discovery to clinical development. Pharm Res 2011;28:2669-2679.
191. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004;279:34682-34690.
192. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 2008;10:601-619.
193. Chernyak BV, Antonenko YN, Domnina LV, Ivanova OY, Lyamzaev KG, Pustovidko AV, Rokitskaya TI, Severina II, Simonyan RA, Trendeleva TA, Zvyagilskaya RA. Novel penetrating cations for targeting mitochondria. Curr Pharm Des 2013;19:2795-2806.
194. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247-261.
195. Willems L, Zatta A, Holgren K, Ashton KJ, Headrick JP. Age-related changes in ischemic tolerance in male and female mouse hearts. J Mol Cell Cardiol 1996;38:245-256.
196. Azhar G, Gao W, Liu L, Wei JK. Ischemia-reperfusion in the adult mouse heart influence of age. Exp Gerontol 1999;34:699-714.
197. Lesnefsky EJ, Gallo W, Ye J, Wittingham TS, Lust WD. Aging increases ischemia-reperfusion injury in the isolated, buffer-perfused heart. J Lab Clin Med 1994;124:843-851.
198. O'Brien JD, Ferguson JH, Howlett SE. Effects of ischemia and reperfusion on isolated ventricular myocytes from young adult and aged Fischer 344 rat hearts. Am J Physiol Heart Circ Physiol 2008;294:H2174-H2183.
199. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusche G, Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008;102:131-135.
200. Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 2007;292:H1764-H1769.
201. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 2007;292:C670-C686.
202. Liu L, Zhu J, Brink PR, Glass PS, Rebecchi MJ. Age-associated differences in the inhibition of mitochondrial permeability transition pore opening by cyclosporine A. Acta Anaesthesiol Scand 2011;55:622-630.
203. + channels of skeletal muscle fibers from young adult and aged rats: Possible involvement of thiol-dependent redox mechanisms in the age-related modifications of their biophysical and pharmacological properties. Mol Pharmacol 1994;46:754-761.
204. ATP channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts. Cardiovasc Res 2001;49:56-68.
205. Heinen A, Winning A, Schlack W, Hollmann MW, Preckel B, Frässdorf J, Weber NC. The regulation of mitochondrial respiration by opening of mKCa channels is age-dependent. Eur J Pharmacol 2008;578:108-113.
206. Lee TM, Su SF, Chou TF, Lee YT, Tsai CH. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334-340.
207. Schulman D, Latchman DS, Yellon DM. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol 2001;281:H1630-H1636.
208. McCully JD, Toyoda Y, Wakiyama H, Rousou AJ, Parker RA, Levitsky S. Age- and gender-related differences in ischemia-reperfusion injury and cardioprotection: Effects of diazoxide. Ann Thorac Surg 2006;82:117-123.
209. Vasconsuelo A, Boland R. Actions of 17β-estradiol and testosterone in the mitochondria and their implications in aging. Ageing Res Rev 2013;12:907-917.
210. Lancaster TS, Jefferson SJ, Hunter JC, Lopez V, Van Eyk JE, Lakatta EG, Korzick DH. Quantitative proteomic analysis reveals novel mitochondrial targets of estrogen deficiency in the aged female rat heart. Physiol Genomics 2012;44:957-969.
211. Hausenloy DJ, Lim SY, Ong SG, Davidson SM, Yellon DM. Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovasc Res 2010;88:67-74.
212. Yu TN, Hong H, Yang JQ, Gao Q, Xia Q. Role of mitochondrial calcium uniporter in cardioprotection induced by ischemic postconditioning in isolated rat heart. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011;40(3):304-308.
213. Xu J, Wang NF, Zhang SZ, Gao Q, Xia Q. Mitochondrial calcium uniporter participates in remote preconditioning induced cardioprotection in rat hearts subjected to ischemia and reperfusion. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2009;25(1):50-54.
214. Zhang SZ, Gao Q, Cao CM, Bruce IC, Xia Q. Involvement of the mitochondrial calcium uniporter in cardioprotection by ischemic preconditioning. Life Sci 2006;78(7):738-745.
215. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009;104(2):189-202.
216. Szewczyk A, Kajma A, Malinska D, Wrzosek A, Bednarczyk P, Zabłocka B, Dołowy K. Pharmacology of mitochondrial potassium channels: Dark side of the field. FEBS Lett 2010;584:2063-2069.
217. Frezza C, Cipolat S, Scorrano L. Organelle isolation: Functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2007;2:287-295.
218. Saks V, Dos Santos P, Gellerich FN, Diolez P. Quantitative studies of enzyme-substrate compartmentation, functional coupling and metabolic channeling in muscle cells. Mol Cell Biochem 1998;184:291-307.
219. Sorgato MC, Keller BU, Stühmer W. Patch-clamping of the inner mitochondrial membrane reveals a voltage-dependent ion channel. Nature 1987;330:498-500.
220. 2+/palmitic acid complexes. Biochim Biophys Acta 2003;1609:153-160.
221. 2+ transfer between sarcoplasmic reticulum subdomains and the mitochondria in heart muscle. J Biol Chem 2008;283:32771-32780.
222. Zick M, Rabl R, Reichert AS. Cristae formation-linking ultrastructure and function of mitochondria. Biochim Biophys Acta 2009;1793:5-19.
223. Fieni F, Lee SB, Jan YN, Kirichok Y. Activity of the mitochondrial calcium uniporter varies greatly between tissues. Nat Commun 2012;3:1317
224. Bednarczyk P, Wieckowski MR, Broszkiewicz M, Skowronek K, Siemen D, Szewczyk A. Putative structural and functional coupling of the mitochondrial BKCa channel to the respiratory chain. PLoS One 2013;8:e68125.
225. Garlid KD, Paucek P. Mitochondrial potassium transport: The K(+) cycle. Biochim Biophys Acta 2003;1606:23-41.
226. Costa AD, Quinlan CL, Andrukhiv A, West IC, Jabůrek M, Garlid KD. The direct physiological effects of mitoK(ATP) opening on heart mitochondria. Am J Physiol Heart Circ Physiol 2006;290:H406-H415.
227. Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev 1999;79:1127-1155.
228. Kunz WS, Kunz W. Contribution of different enzymes to flavoprotein fluorescence of isolated rat liver mitochondria. Biochim Biophys Acta 1985;841:237-246.
229. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007;1767:1007-1031.
230. Liu Y, Sato T, Seharaseyon J, Szewczyk A, O'Rourke B, Marbán E. Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Ann N Y Acad Sci 1999;874:27-37.
231. + channels modulate cardiac mitochondrial function. Am J Physiol 1998;275:H1567-H1576.
232. Fornai M, Antonioli L, Colucci R, Pellegrini C, Giustarini G, Testai L, Martelli A, Matarangasi A, Natale G, Calderone V, Scarpignato C, Tuccori M, Blandizzi C. NSAID-induced enteropathy: Are the currently available selective COX-2 inhibitors all the same? J Pharmacol Exp Ther 2014;348:86-95.
233. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, Critz SD. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005;97:329-336.
234. Jung DW, Davis MH, Brierley GP. Estimation of matrix pH in isolated heart mitochondria using a fluorescent probe. Anal Biochem 1989;178:348-354.
235. 2+ overload in rat cardiac mitochondria. J Physiol 1999;519:347-360.
236. Gunter TE, Gunter KK, Sheu SS, Gavin CE. Mitochondrial calcium transport: Physiological and pathological relevance. Am J Physiol 1994;267:C313-C339.
237. Zoratti M, Szabò I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.
238. Bernardi P, Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: A critical appraisal. J Bioenerg Biomembr 1996;28:131-138.